Heron Therapeutics (HRTX) Profit After Tax (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Profit After Tax data on file, last reported at -$8.1 million in Q1 2026.

• Quarterly Profit After Tax fell 407.82% year-over-year to -$8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.9 million (down 299.75% YoY) and the FY2025 annual result came in at -$20.2 million, down 48.71% from the prior year.
• Profit After Tax slipped to -$8.1 million in Q1 2026, from -$2.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $3.7 million in Q4 2024 to a low of -$63.9 million in Q1 2022.
• A 5-year average of -$19.7 million and a median of -$10.7 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2025 — Profit After Tax jumped 183.39% — and 2026, when it slumped 407.82%.
• Tracing HRTX's Profit After Tax over 5 years: stood at -$19.9 million in 2022, then jumped by 46.03% to -$10.7 million in 2023, then soared by 134.16% to $3.7 million in 2024, then slumped by 180.29% to -$2.9 million in 2025, then slumped by 175.79% to -$8.1 million in 2026.
• The last three Profit After Tax figures came in at -$8.1 million (Q1 2026), -$2.9 million (Q4 2025), and -$17.5 million (Q3 2025), per Business Quant data.